CK2α phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patients

International Journal of Cancer

Volumn 136, Issue 4, 2015, Pages 797-809

  Bae, Jun Sang ^a   Park, See Hyoung ^b   Kim, Kyoung Min ^a   Kwon, Keun Sang ^a   Kim, Chan Young ^a   Lee, Hun Ku ^a   Park, Byung Hyun ^a   Park, Ho Sung ^a   Lee, Ho ^a   Moon, Woo Sung ^a   Chung, Myoung Ja ^a   Sylvester, Karl G ^b   Jang, Kyu Yun ^a  

^a Chonbuk National University Medical School   (South Korea)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma; CK2; DBC1; Phosphorylation; Stomach

Indexed keywords

CASEIN KINASE II; CASEIN KINASE II ALPHA; DELETED IN BREAST CANCER 1 PROTEIN; GELATINASE A; GELATINASE B; TUMOR PROTEIN; UNCLASSIFIED DRUG; DBC1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME BINDING; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH CARCINOMA; SURVIVAL TIME; TUMOR INVASION; ADENOCARCINOMA; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; ENZYMOLOGY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROGNOSIS; PROTEIN PROCESSING; STOMACH TUMOR;

ADENOCARCINOMA; CASEIN KINASE II; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84918798374     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29043     Document Type: Article

References (49)

1. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003;17: 349-68
2. Canton DA, Litchfield DW. The shape of things to come: An emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton. Cell Signal 2006;18:267-75
3. Ruzzene M, Pinna LA. Addiction to protein kinase CK2: A common denominator of diverse cancer cells? Biochim Biophys Acta 2010;1804:499-504
4. Song DH, Dominguez I, Mizuno J, et al. CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J Biol Chem 2003;278:24018-25
5. Landesman-Bollag E, Romieu-Mourez R, Song DH, et al. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001;20:3247-57
6. Di Maira G, Salvi M, Arrigoni G, et al. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 2005;12:668-77
7. Chantome A, Pance A, Gauthier N, et al. Casein kinase II-mediated phosphorylation of NFkappaB p65 subunit enhances inducible nitricoxide synthase gene transcription in vivo. J Biol Chem 2004;279:23953-60
8. Bousset K, Oelgeschlager MH, Henriksson M, et al. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II. Cell Mol Biol Res 1994;40:501-11
9. Al-Khouri AM, Ma Y, Togo SH, et al. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 2005;280:35195-202
10. Kim JS, Eom JI, Cheong JW, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007;13:1019-28
11. Scaglioni PP, Yung TM, Cai LF, et al. A CK2- dependent mechanism for degradation of the PML tumor suppressor. Cell 2006;126:269-83
12. Faust RA, Gapany M, Tristani P, et al. Elevated protein kinase CK2 activity in chromatin of head and neck tumors: Association with malignant transformation. Cancer Lett 1996;101:31-5
13. Stalter G, Siemer S, Becht E, et al. Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun 1994;202:141-7
14. Zou J, Luo H, Zeng Q, et al. Protein kinase CK2alpha is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med 2011; 9:97
15. Laramas M, Pasquier D, Filhol O, et al. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007;43:928-34
16. Lin KY, Tai C, Hsu JC, et al. Overexpression of nuclear protein kinase CK2 alpha catalytic subunit (CK2alpha) as a poor prognosticator in human colorectal cancer. PLoS One 2011;6: e17193
17. Lin KY, Fang CL, Chen Y, et al. Overexpression of nuclear protein kinase CK2 Beta subunit and prognosis in human gastric carcinoma. Ann Surg Oncol 2010;17:1695-702
18. Kim JE, Chen J, Lou Z. DBC1 is a negative regulator of SIRT1. Nature 2008;451:583-6
19. Zhao W, Kruse JP, Tang Y, et al. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008;451:587-90
20. Zhang Y, Gu Y, Sha S, et al. DBC1 is overexpressed and associated with poor prognosis in colorectal cancer. Int J Clin Oncol 2014;19:106-12
21. Park HS, Bae JS, Noh SJ, et al. Expression of DBC1 and androgen receptor predict poor prognosis in diffuse large B cell lymphoma. Transl Oncol 2013;6:370-81
22. Noh SJ, Kang MJ, Kim KM, et al. Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients. Pathology 2013;45:574-80
23. Kim JR, Moon YJ, Kwon KS, et al. Expression of SIRT1 and DBC1 is associated with poor prognosis of soft tissue sarcomas. PLoS One 2013;8: e74738
24. Kim SH, Kim JH, Yu EJ, et al. The overexpression of DBC1 in esophageal squamous cell carcinoma correlates with poor prognosis. Histol Histopathol 2012;27:49-58
25. Lee H, Kim KR, Noh SJ, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 2011;42: 204-13
26. Hiraike H, Wada-Hiraike O, Nakagawa S, et al. Expression of DBC1 is associated with nuclear grade and HER2 expression in breast cancer. Exp Ther Med 2011;2:1105-9
27. Cha EJ, Noh SJ, Kwon KS, et al. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 2009;15: 4453-9
28. Park SH, Riley Pt, Frisch SM. Regulation of anoikis by deleted in breast cancer-1 (DBC1) through NF-kappaB. Apoptosis 2013;18:949-62
29. Nin V, Escande C, Chini CC, et al. Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase. J Biol Chem 2012;287:23489-501
30. Hiraike H, Wada-Hiraike O, Nakagawa S, et al. Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer 2010;102: 1061-7
31. Li Z, Chen L, Kabra N, et al. Inhibition of SUV39H1 methyltransferase activity by DBC1. J Biol Chem 2009;284:10361-6
32. Fu J, Jiang J, Li J, et al. Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J Biol Chem 2009;284:6832-40
33. Sung JY, Kim R, Kim JE, et al. Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 2010;101:1738-44
34. Kim W, Kim J-E. Deleted in breast cancer 1 (DBC1) deficiency results in apoptosis of breast cancer cells through impaired responses to UVinduced DNA damage. Cancer Lett 2013;333: 180-6
35. Kang H, Jung JW, Kim MK, et al. CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNAdamage. PLoS One 2009;4:e6611
36. Zschoernig B, Mahlknecht U. Carboxy-terminal phosphorylation of SIRT1 by protein kinase CK2. Biochem Biophys Res Commun 2009;381:372-7
37. Bosman F, Carneiro F, Hruban R, et al. WHO classification of tumours of the digestive system, 4th edn. Lyon: IARC, 2010
38. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
39. Parkin DM. International variation. Oncogene 2004;23:6329-40
40. Edge S, Cancer AJCo. AJCC cancer staging handbook: from the AJCC cancer staging manual. New York, NY: Springer, 2010
41. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275-82
42. Jang KY, Noh SJ, Lehwald N, et al. SIRT1 and c- Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One 2012;7:e45119
43. Zannini L, Buscemi G, Kim JE, et al. DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage. J Mol Cell Biol 2012;4:294-303
44. Kim Y-K, Lee KJ, Jeon H, et al. Protein kinase CK2 is inhibited by human nucleolar phosphoprotein p140 in an inositol hexakisphosphatedependent manner. J Biol Chem 2006;281: 36752-7
45. Faust RA, Niehans G, Gapany M, et al. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem Cell Biol 1999;31:941-9
46. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74
47. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34
48. Ku MJ, Park JW, Ryu BJ, et al. CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells. Bioorg Med Chem Lett 2013;23:5609-13
49. Escande C, Chini CC, Nin V, et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest 2010;120:545-58.